ARMGO Pharma Inc. Receives $1 Million Award From to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
4/17/2013 9:23:43 AM
More...
|
ARMGO Pharma Inc. Announces Data Which Supports Its Rycal Program as a Novel Approach for the Treatment of Stress-Induced Cognitive Disorders
8/31/2012 8:51:55 AM
More...
|